Vanda Pharmaceuticals (VNDA) Net Margin (2010 - 2026)

Vanda Pharmaceuticals has disclosed Net Margin across 17 years of filings, most recently posting 93.82% for Q1 2026.

• Net Margin for Q1 2026 came in at 93.82%, down 3488.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 109.99% (down 8802.0% YoY), and the FY2025 annual result was 102.02%, down 9251.0% from the prior year.
• Net Margin came in at 93.82% for Q1 2026 at Vanda Pharmaceuticals, up from 246.83% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 10.64% in Q4 2022 to a low of 246.83% in Q4 2025.
• The 5-year median for Net Margin is 8.95% (2024), against an average of 30.42%.
• Across the five-year window, Net Margin surged 1585 bps in 2023 and tumbled 23767 bps in 2025, its largest moves.
• Vanda Pharmaceuticals' Net Margin stood at 10.64% in 2022, then tumbled by 150 bps to 5.28% in 2023, then plunged by 74 bps to 9.17% in 2024, then tumbled by 2592 bps to 246.83% in 2025, then jumped by 62 bps to 93.82% in 2026.
• The last three Net Margin figures came in at 93.82% (Q1 2026), 246.83% (Q4 2025), and 40.15% (Q3 2025), per Business Quant data.